26 August 2023: Database Analysis
An Immune-Related Gene Signature for Predicting Survival and Immunotherapy Efficacy in Esophageal Adenocarcinoma
Chuang Yang 1BC* , Feng Cao 2EF* , Yan He 2A*DOI: 10.12659/MSM.940157
Med Sci Monit 2023; 29:e940157
Supplementary Table 6 The overall, TP53 and MUC16 mutation rates in the low-risk and high-risk groups.
| Variable | High-risk | Low-risk | χ2 | P |
|---|---|---|---|---|
| Overall | ||||
| Wild | 0% (0) | 7.69% (3) | ||
| Mutant | 100% (37) | 92.31% (36) | 0.24a | |
| TP53 | ||||
| Wild | 11% (4) | 36% (12) | ||
| Mutant | 89% (33) | 64% (25) | 3.9 | 0.048b |
| MUC16 | ||||
| Wild | 84% (31) | 59% (23) | ||
| Mutant | 16% (6) | 41% (16) | 5.68 | 0.017c |
| a overall mutation rate, calculated by Fisher’s exact test; b TP53 mutation rate, calculated by Calibration chi-square test; c MUC16 mutation rate, calculated by chi-square test. | ||||